Sub Banner Image

Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?

Equities

Zacks Investment Research

·

August 19, 2025

·

Barchart

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics. The addition of Seagen...

More from

Barchart

More

Equities

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.